Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

NCT07581704 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Sirolimus
BIOLOGICAL: Teclistamab
BIOLOGICAL: Talquetamb

Sponsor

Christopher Strouse